menu
    • menu
    [{"orgOrder":0,"company":"Mission Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"MTX652","moa":"USP-30","graph1":"Nephrology","graph2":"IND Enabling","graph3":"Mission Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mission Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Mission Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mission Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"MTX652","moa":"USP-30","graph1":"Nephrology","graph2":"IND Enabling","graph3":"Mission Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mission Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Mission Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"TST004","moa":"MASP-2","graph1":"Nephrology","graph2":"IND Enabling","graph3":"Transcenta Holding","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Transcenta Holding \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Transcenta Holding \/ Inapplicable"},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"TST004","moa":"MASP-2","graph1":"Nephrology","graph2":"IND Enabling","graph3":"Transcenta Holding","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Transcenta Holding \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Transcenta Holding \/ Inapplicable"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"AUR200","moa":"BAFF\/APRIL","graph1":"Nephrology","graph2":"IND Enabling","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aurinia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Aurinia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alebund Pharmaceuticals","sponsor":"3H Health Investment","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Series B Financing","leadProduct":"AP-302","moa":"MASP-2","graph1":"Nephrology","graph2":"IND Enabling","graph3":"Alebund Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alebund Pharmaceuticals \/ 3H Health Investment","highestDevelopmentStatusID":"5","companyTruncated":"Alebund Pharmaceuticals \/ 3H Health Investment"},{"orgOrder":0,"company":"Purespring Therapeutics","sponsor":"Sofinnova Partners","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Series B Financing","leadProduct":"PS-002","moa":"Undisclosed","graph1":"Nephrology","graph2":"IND Enabling","graph3":"Purespring Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Purespring Therapeutics \/ Sofinnova Partners","highestDevelopmentStatusID":"5","companyTruncated":"Purespring Therapeutics \/ Sofinnova Partners"},{"orgOrder":0,"company":"Aerovate Therapeutics","sponsor":"Jade Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Merger","leadProduct":"JADE-001","moa":"Undisclosed","graph1":"Nephrology","graph2":"IND Enabling","graph3":"Aerovate Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aerovate Therapeutics \/ Jade Biosciences","highestDevelopmentStatusID":"5","companyTruncated":"Aerovate Therapeutics \/ Jade Biosciences"},{"orgOrder":0,"company":"Ventus Therapeutics","sponsor":"Novo Nordisk","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"VENT-01","moa":"NLRP3","graph1":"Nephrology","graph2":"IND Enabling","graph3":"Ventus Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ventus Therapeutics \/ Novo Nordisk","highestDevelopmentStatusID":"5","companyTruncated":"Ventus Therapeutics \/ Novo Nordisk"},{"orgOrder":0,"company":"Concept Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Nephrology","graph2":"IND Enabling","graph3":"Concept Medical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Concept Medical \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Concept Medical \/ Inapplicable"},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"ATA3219","moa":"Undisclosed","graph1":"Nephrology","graph2":"IND Enabling","graph3":"Atara Biotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Atara Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Atara Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sana Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"SC291","moa":"CD19","graph1":"Nephrology","graph2":"IND Enabling","graph3":"Sana Biotechnology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sana Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Sana Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Delta Crystallon","sponsor":"Serenity Bioworks","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"NETHERLANDS","productType":"Protein","year":"2022","type":"Acquisition","leadProduct":"Recombinant Human HspB5","moa":"Undisclosed","graph1":"Nephrology","graph2":"IND Enabling","graph3":"Delta Crystallon","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Delta Crystallon \/ Serenity Bioworks","highestDevelopmentStatusID":"5","companyTruncated":"Delta Crystallon \/ Serenity Bioworks"},{"orgOrder":0,"company":"Saniona","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"DENMARK","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"SAN903","moa":"KCa3.1","graph1":"Nephrology","graph2":"IND Enabling","graph3":"Saniona","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Saniona \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Saniona \/ Inapplicable"},{"orgOrder":0,"company":"Saniona","sponsor":"University of Arhus","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"DENMARK","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"SAN903","moa":"KCa3.1","graph1":"Nephrology","graph2":"IND Enabling","graph3":"Saniona","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Saniona \/ University of Arhus","highestDevelopmentStatusID":"5","companyTruncated":"Saniona \/ University of Arhus"},{"orgOrder":0,"company":"Federation Bio","sponsor":"Horizons Ventures","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Probiotic","year":"2020","type":"Series A Financing","leadProduct":"Human Gut Microbiome","moa":"Undisclosed","graph1":"Nephrology","graph2":"IND Enabling","graph3":"Federation Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Federation Bio \/ Horizons Ventures","highestDevelopmentStatusID":"5","companyTruncated":"Federation Bio \/ Horizons Ventures"},{"orgOrder":0,"company":"Aerovate Therapeutics","sponsor":"Jade Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Merger","leadProduct":"JADE-001","moa":"APRIL","graph1":"Nephrology","graph2":"IND Enabling","graph3":"Aerovate Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aerovate Therapeutics \/ Jade Biosciences","highestDevelopmentStatusID":"5","companyTruncated":"Aerovate Therapeutics \/ Jade Biosciences"},{"orgOrder":0,"company":"Aerovate Therapeutics","sponsor":"Jade Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Merger","leadProduct":"JADE-001","moa":"APRIL","graph1":"Nephrology","graph2":"IND Enabling","graph3":"Aerovate Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aerovate Therapeutics \/ Jade Biosciences","highestDevelopmentStatusID":"5","companyTruncated":"Aerovate Therapeutics \/ Jade Biosciences"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Aerovate Therapeutics

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            Aerovate Therapeutics

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : JADE-001

                            Therapeutic Area : Nephrology

                            Study Phase : IND Enabling

                            Sponsor : Jade Biosciences

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            Jade Merges with Aerovate, Secures $300M in Private Placement Funding

                            Details : The combined company will focus on advancing Jade’s portfolio of novel biologics, including JADE-001, a promising anti-APRIL monoclonal antibody for IgA nephropathy.

                            Product Name : JADE-001

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            April 28, 2025

                            Lead Product(s) : JADE-001

                            Therapeutic Area : Nephrology

                            Highest Development Status : IND Enabling

                            Sponsor : Jade Biosciences

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Purespring Therapeutics

                            United Kingdom arrow
                            AACR Annual meeting
                            Not Confirmed

                            Purespring Therapeutics

                            United Kingdom arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PS-002

                            Therapeutic Area : Nephrology

                            Study Phase : IND Enabling

                            Sponsor : Sofinnova Partners

                            Deal Size : $105.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Purespring Therapeutics Raises $105M to Transform Kidney Disease Treatment

                            Details : The proceeds will be used to support Purespring’s pipeline including the initiation of a Phase I/II clinical trial of PS-002 for IgAN, a chronic kidney disease primarily affecting young adults.

                            Product Name : PS-002

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            September 10, 2024

                            Lead Product(s) : PS-002

                            Therapeutic Area : Nephrology

                            Highest Development Status : IND Enabling

                            Sponsor : Sofinnova Partners

                            Deal Size : $105.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Atara Biotherapeutics

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            Atara Biotherapeutics

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ATA3219

                            Therapeutic Area : Nephrology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Atara Biotherapeutics Receives FDA IND Clearance for ATA3219 in Lupus Nephritis

                            Details : ATA3219 is an allogeneic, anti-CD19 chimeric antigen receptor (CAR) T-cell monotherapy, e=which is being evaluated for the treatment of Lupus Nephritis.

                            Product Name : ATA3219

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            February 29, 2024

                            Lead Product(s) : ATA3219

                            Therapeutic Area : Nephrology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Concept Medical

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            Concept Medical

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sirolimus

                            Therapeutic Area : Nephrology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Concept Medical Receives FDA IDE Approval for Magictouch AVF Indication

                            Details : FDA approved MagicTouch AVF, a Sirolimus drug-coated balloon catheter, for clinical trials treating stenotic lesions of Arteriovenous Fistula in patients with chronic renal failure.

                            Product Name : MagicTouch AVF

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            February 04, 2024

                            Lead Product(s) : Sirolimus

                            Therapeutic Area : Nephrology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Aurinia Pharmaceuticals

                            Canada arrow
                            AACR Annual meeting
                            Not Confirmed

                            Aurinia Pharmaceuticals

                            Canada arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AUR200

                            Therapeutic Area : Nephrology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Aurinia Submits IND Application to US Food & Drug Administration for AUR 200

                            Details : AUR200s a highly potent and specific Fc-fusion protein, which is a BAFF/APRIL inhibitor. Currently, it is being evaluated in the IND enabling studies for the treatment of autoimmune diseases such as IgA nephropathy and systemic lupus erythematosus.

                            Product Name : AUR200

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            December 20, 2023

                            Lead Product(s) : AUR200

                            Therapeutic Area : Nephrology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Mission Therapeutics

                            United Kingdom arrow
                            AACR Annual meeting
                            Not Confirmed

                            Mission Therapeutics

                            United Kingdom arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MTX652

                            Therapeutic Area : Nephrology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Mission Therapeutics Announces US FDA Approval to Initiate Phase II Clinical Trial of its Lead Asset MTX652 in...

                            Details : MTX652 is a potent and selective compound designed to improve mitochondrial quality and function by enhancing mitophagy through inhibition of USP30 enzyme. It is being evaluated for the treatment of acute kidney injury (AKI) following cardiac surgery.

                            Product Name : MTX652

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            December 14, 2023

                            Lead Product(s) : MTX652

                            Therapeutic Area : Nephrology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Nkarta Therapeutics

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            Nkarta Therapeutics

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NKX019

                            Therapeutic Area : Nephrology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Nkarta Receives FDA Clearance of IND Application for NKX019 in Lupus Nephritis

                            Details : NKX019 is an allogeneic, cryopreserved, off-the-shelf immunotherapy candidate that uses natural killer (NK) cells derived from the peripheral blood of healthy adult donors, which is investigated for the treatment of Lupus Nephritis.

                            Product Name : NKX019

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            October 17, 2023

                            Lead Product(s) : NKX019

                            Therapeutic Area : Nephrology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Sana Biotechnology

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            Sana Biotechnology

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SC291

                            Therapeutic Area : Nephrology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC291, a Hypoimmune-mod...

                            Details : SC291, a Hypoimmune-modified, CD19-directed Allogeneic CAR T Therapy, for Patients with Lupus Nephritis, Extrarenal Lupus, and ANCA-associated Vasculitis.

                            Product Name : SC291

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            September 11, 2023

                            Lead Product(s) : SC291

                            Therapeutic Area : Nephrology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Tonix Pharmaceuticals Holding Corp

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            Tonix Pharmaceuticals Holding Corp

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TNX-1500

                            Therapeutic Area : Nephrology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Tonix Pharmaceuticals Announces IND Clearance for TNX-1500 (anti-CD40L mAb) for the Prevention of Organ Reject...

                            Details : TNX-1500 (Fc-modified anti-CD40L mAb) is a humanized monoclonal antibody that interacts with the CD40-ligand, it is being developed for the prevention of allograft and xenograft rejection, for the treatment of autoimmune diseases and for the prevention o...

                            Product Name : TNX-1500

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            April 05, 2023

                            Lead Product(s) : TNX-1500

                            Therapeutic Area : Nephrology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Everest Medicines

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            Everest Medicines

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Zetomipzomib

                            Therapeutic Area : Nephrology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Everest Medicines Announces Investigational New Drug Application Acceptance of Zetomipzomib in China

                            Details : KZR-616 (zetomipzomib) is a novel, first-in-class, selective immunoproteasome inhibitor. It is currently being evaluated for the treatment of Lupus Nephritis.

                            Product Name : KZR-616

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 12, 2023

                            Lead Product(s) : Zetomipzomib

                            Therapeutic Area : Nephrology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth